Agenus Email Format
Biotechnology Research
・
201-500 employees
・
Lexington, MA, USA
Agenus is a biotechnology company specializing in immuno-oncology, developing antibody therapeutics, adoptive cell therapies, and adjuvants to expand cancer immunotherapy treatment options for patients.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@agenusbio.com
Company Overview
Industry
Biotechnology Research
Founded
1994
Headquarters
Lexington, MA, USA
Revenue
$100M+
FUNDING Stage
Public
Website
Key Executives
Garo H. Armen (Chairman and Chief Executive Officer), Garo H. Armen (interim Chief Financial Officer and Principal Financial Officer), Craig Winter (Chief Information Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Agenus?
Agenus uses the first.last format, so Jane Smith would be jane.smith@agenusbio.com.
What cancer types is Agenus targeting with its botensilimab and balstilimab combination?
Agenus is advancing the botensilimab plus balstilimab combination across multiple solid tumor types, with its lead focus on metastatic colorectal cancer, checkpoint-refractory melanoma, and pancreatic cancer. The Phase 3 BATTMAN trial, which enrolled its first patient in April 2026, targets refractory MSS metastatic colorectal cancer.
Who leads Agenus as CEO in 2026?
Garo H. Armen serves as Chairman and Chief Executive Officer of Agenus in 2026. He also holds the role of interim Chief Financial Officer and Principal Financial Officer.
How can I find and verify a contact at Agenus for outreach?
Agenus follows the first.last@agenusbio.com email format, so building or verifying contacts is straightforward. Tools like Clay can help you confirm specific employee emails and enrich your outreach list with up-to-date Agenus contact data.
When was Agenus founded and where is it headquartered?
Agenus was founded in 1994, originally as Antigenics, and is headquartered in Lexington, MA. The company has been focused on cancer immunotherapy for over 30 years and is publicly traded on Nasdaq under the ticker AGEN.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating